Vir Biotechnology (VIR)

• Market cap: $606M
• 1 day: -0.46%
• 5 days: 0.69%
• 1 month: -20.44%
• 3 months: -6.44%
• 6 months: -52.61%
• Year to date: -40.03%
• 1 year: -49.42%
• 5 years: -90.01%
• 10 years: -68.90%
• Sector: Healthcare
• Industry: Biotechnology

About: Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

Employees: 408

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

93% more call options, than puts

Call options by funds: $1.71M | Put options by funds: $884K

35% more repeat investments, than reductions

Existing positions increased: 81 | Existing positions reduced: 60

11.51% more ownership

Funds ownership: 67.99% [Q1] → 79.5% (+11.51%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]

8% less capital invested

Capital invested by funds: $604M [Q1] → $554M (-$50.3M) [Q2]

10% less funds holding

Funds holding: 232 [Q1] → 208 (-24) [Q2]

42% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 38

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $12 175% upside
• Avg. target: $12 175% upside
• High target: $12 175% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Raymond James Sean McCutcheon

175% upside $12

Outperform Initiated

11 Jul 2025